IUPAC/Chemical Name
3-Isoxazolecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-
InChi Key
GZKDXUIWCNCNBJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H26N4O5S/c1-14-13-18(23-29-14)19(25)21-12-11-15-7-9-17(10-8-15)30(27,28)24-20(26)22-16-5-3-2-4-6-16/h7-10,13,16H,2-6,11-12H2,1H3,(H,21,25)(H2,22,24,26)
SMILES Code
O=C(C1=NOC(C)=C1)NCCC2=CC=C(S(=O)(NC(NC3CCCCC3)=O)=O)C=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
434.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dalla Vedova R, Cadel S, D'Alò G. Studio sull'attività protettiva della glisolamide sulla aterosclerosi sperimentale nel coniglio [Study of the protective activity of glisolamide on experimental atherosclerosis in the rabbit]. G Clin Med. 1979 Nov;60(11):911-26. Italian. PMID: 546672.
2: Cerri L, Dalla Vedova R, Groppetti A. Studio farmacocinetico nel ratto di una nuova molecola ipoglicemizzante: la glisolamide [Pharmacokinetic study in the rat of a new hypoglycemic agent: glisolamide]. G Clin Med. 1979 Nov;60(11):903-10. Italian. PMID: 546671.
3: D'Alò G, Dalla Vedova R, Cadel S, Campi G, Wassermann A. Glisolamide una nuova sulfanilurea. Caratteristiche farmacologiche [Glisolamide, a new sulfanylurea. Pharmacologic characteristics]. Boll Chim Farm. 1978 Jun;117(6):348-67. Italian. PMID: 743381.
4: Vigneri R, Pezzino V, Wong KY, Goldfine ID. Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells. J Clin Endocrinol Metab. 1982 Jan;54(1):95-100. doi: 10.1210/jcem-54-1-95. PMID: 7033271.
5: Goldfine ID, Iwamoto Y, Pezzino V, Trischitta V, Purrello F, Vigneri R. Effects of biguanides and sulfonylureas on insulin receptors in cultured cells. Diabetes Care. 1984 May-Jun;7 Suppl 1:54-8. PMID: 6734405.
6: Runci FM, Cerretani D, Cerri D, Segre G. Pharmacokinetics in man of glysolamide, a low-dose oral antidiabetic drug. Farmaco Prat. 1984 Dec;39(12):424-30. PMID: 6529984.
7: Dalla Vedova R, Cadel S, Wassermann A. Attività "in vitro" della glisolamide sulla emocoagulazione [In vitro effect of glysolamide on blood coagulation]. Boll Chim Farm. 1979 Jan;118(1):28-30. Italian. PMID: 454528.
